Semaglutide, the latter emerges as the preferred option
So, Ozempic is expected to be effective regardless of whether its injected into the abdomen, thigh, or upper arm
According to Health Canada data, spending on Ozempic increased from CAD $13.5 million in 2019 to CAD $227 million in 2021, with 36-74% of private insurance claims potentially from patients without diabetes seeking weight loss benefits
Efficacy and safety of dulaglutide monotherapy versus metformin in type 2 diabetes in a randomized controlled trial (AWARD-3)
Overall, the incidence of adverse events is generally higher in diabetes patients compared to obesity patients
They are not over-the-counter and necessitate ongoing monitoring by a qualified healthcare professional